Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Once was enough

Realizing it may have caught lightning in a bottle with its licensing arrangement for Roche's CellCept, Aspreva Pharmaceuticals Corp. gave up its search for new in-licensing candidates and instead agreed to sell itself to Galenica Group. The Swiss company, in turn, needed a North American presence as it awaits an FDA response on an NDA for its Ferinject iron replacement.

Aspreva (TSX:ASV; ASPV, Victoria, B.C.) began life by scouring big pharma's shelves for marketed products with potential in peripheral indications,

Read the full 792 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers